title: Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant).
abstract: The present study assesses the endocrinological, endometrial histology and vaginal ultrasound profiles of nomegestrol acetate subdermal implant users at varying times after insertion. Follicle stimulatory hormone, luteinizing hormone, oestradiol, progesterone, vaginal ultrasound assessment of the ovaries and the histological dating of the endometrium were serially assessed for a period of 50 days immediately after the insertion, and after at 6 months and 12 months of use. The endocrinological results of this prospective observational clinical trial indicated that 75% of the cycles across the study period in Uniplant users were anovulatory, 63% showing development of a persistent non-luteinized follicle. Anovulatory cycles devoid of follicular development were seen primarily in the first months after Uniplant insertion. Ovulatory cycles represented 25% of the Uniplant cycles. Inadequate luteal phase or disregulation of follicular growth was a common feature of ovulatory cycles. In conclusion, these findings suggest that the contraceptive mechanisms of a single nomegestrol acetate subdermal implant involve prevention of follicular growth, development of a persistent non-luteinized follicle, inadequate luteal phase and disruption of the endometrial architecture.
authors.affiliation: Research Institute for the Mother and Child, School of Medicine, University of Chile, San Borja Arriaran Clinical Hospital, Santiago.
authors.forename: L
authors.initials: L
authors.lastname: Devoto
authors.forename: P
authors.initials: P
authors.lastname: Kohen
authors.forename: K
authors.initials: K
authors.lastname: Barnhart
authors.forename: F
authors.initials: F
authors.lastname: Alba
authors.forename: R
authors.initials: R
authors.lastname: Pommer
authors.forename: I
authors.initials: I
authors.lastname: Retamales
authors.forename: E
authors.initials: E
authors.lastname: Coutinho
mesh_terms: D000328:Adult; D001706:Biopsy; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D004343:Drug Implants; D004717:Endometrium / Q000473:pathology*; D005069:Evaluation Studies as Topic; D005260:Female; D006728:Hormones / Q000097:blood*; D006801:Humans; D008137:Longitudinal Studies; D008183:Luteal Phase / Q000187:drug effects; D008535:Megestrol; D009649:Norpregnadienes / Q000627:therapeutic use*; D006080:Ovarian Follicle / Q000254:growth & development; D010053:Ovary / Q000000981:diagnostic imaging*; D010060:Ovulation / Q000187:drug effects; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012016:Reference Values; D014463:Ultrasonography
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D006728:Hormones; D009649:Norpregnadienes; D045167:Progesterone Congeners; C038501:nomegestrol acetate; D008535:Megestrol